[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-stent-related-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-stent-related-symptoms":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642199","phase-3-assessing-suzetrigine-for-pain-reduction-following-ureteroscopic-surgery-100642199",false,"NCT07654296","Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery","Multimodal Analgesia Pathway Assessing Role of Suzetrigine for the Reduction of Opioid Use Following Ureteroscopic Surgery","Inclusion Criteria:\n\n* Patients undergoing ureteroscopy between ages 21 to 80 at BWFH (Brigham \\& Women's Faulkner Hospital) by one of the department's high volume endoscopic surgeons. Patient who are or not pre-stented prior to surgery will be included (these will be assessed via stratification within a secondary analysis).\n* Patients able to consent for their own medical care (i.e. consent able to be obtained directly from patient and does not require a healthcare proxy or guardian)\n\nExclusion Criteria:\n\n* Regular opioid use prior to surgery or significant substance abuse concerns.\n* Inability of patient to provide their own consent (i.e. lack capacity).","ALL","21 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Urologic surgery has advanced with new technologies to allow less invasive management of common afflictions such as kidney stones, these procedures are notoriously painful as the ureter must be dilated to accommodate any instruments, and a ureteral stent is often left following surgery to allow for adequate healing. Unfortunately, stents are poorly tolerated by a significant number of patients, with up to 100% complaining of bothersome pain and 10% of patients with unplanned healthcare visits. Further complicating kidney stone management is the frequency of concurrent chronic kidney disease (CKD) or acute kidney injury (AKI) that prohibits many patients from taking NSAIDs which limits pain management options. There is now a push to treat these patients with multimodal analgesia to provide better care and reduce opioid use. Suzetrigine is a new a first-in-class selective inhibitor of the NaV1.8 sodium channel that functions as a non-opioid analgesic developed to treat acute pain and neuropathic pain. This study assesses the addition of suzetrigine to standard-of-care multimodal analgesia. We hypothesize a demonstrated decrease in opioid use, decrease Emergency Room visits within 30 days, decrease the number of unplanned care encounters.",[27,28,29,30,31],"Opioid Consumption, Postoperative","Multimodal Analgesia","Ureteroscopy","Ureteral Stents","Ureteral Stent-Related Symptoms",[28,33,34,35],"Postoperative Opioid Consumption","ureteroscopy","ureteral stents","NOT_YET_RECRUITING","2026-06-12",{"date":39,"type":40},"2026-06-17","ACTUAL",{"date":42,"type":21},"2026-08-01",{"date":44,"type":21},"2027-03-31",{"name":46,"class":47},"Brigham and Women's Hospital","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100638175","comfij-versus-conventional-double-j-stent-for-ureteral-stent-symptoms-100638175","NCT07627828","ComfiJ Versus Conventional Double-J Stent for Ureteral Stent Symptoms","Evaluation of Stent-Related Symptoms After ComfiJ Ureteric Stent Versus Conventional Double-J Ureteric Stent: A Prospective Multicenter Randomized Controlled Trial","COMFIJ-DJS","Inclusion Criteria:\n\n* Age 18 to 80 years.\n* Adult patients undergoing unilateral ureteroscopy or retrograde intrarenal surgery for ureteric or renal stones.\n* Intraoperative confirmation that short-term postoperative ureteric stenting for approximately 2 weeks is clinically indicated.\n* Indications for postoperative stenting may include ureteric edema, minor ureteric mucosal trauma, need for ureteric dilatation, ureteral access sheath use with expected postoperative edema, impacted stone, residual dust or fragments requiring temporary drainage, or prolonged procedure.\n* Ability to understand and complete the Arabic Ureteral Stent Symptom Questionnaire.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Cases in which no postoperative ureteric stent is clinically indicated.\n* Cases requiring prolonged urinary drainage or major reconstructive decision-making.\n* Bilateral ureteroscopy or retrograde intrarenal surgery.\n* Solitary kidney.\n* Major ureteric injury or ureteric perforation.\n* Preoperative febrile urinary tract infection or sepsis.\n* Pregnancy or breastfeeding.\n* Neurogenic bladder.\n* Overactive bladder syndrome.\n* Major neurological disease or psychiatric disease affecting symptom reporting.\n* History of major bladder, prostate, or pelvic surgery likely to confound stent-related symptoms.\n* Concomitant use of alpha-blockers, anticholinergics, chronic analgesics, or other medications likely to alter symptom evaluation.\n* Other acute medical conditions that might influence the Ureteral Stent Symptom Questionnaire pain score, including acute pancreatitis, acute gastroenteritis, or musculoskeletal disorders.\n* Known allergy to any study-related medication or device material.\n* Inability to comply with the follow-up schedule.","18 Years",{"count":59,"type":21},150,[61],"NA","This prospective multicenter randomized controlled trial will compare stent-related symptoms after placement of a ComfiJ ureteral stent versus a conventional double-J ureteral stent in adult patients undergoing unilateral ureteroscopy or retrograde intrarenal surgery for urinary stones when short-term postoperative ureteral stenting is clinically indicated. Eligible patients will be randomized intraoperatively after the operating surgeon confirms the need for postoperative stenting. The primary outcome will be the Ureteral Stent Symptom Questionnaire urinary symptoms domain score on postoperative day 14 before planned stent removal.",[31,64,65],"Ureteral Calculi","Urolithiasis",[67,68,69,29],"ComfiJ ureteral stent","Conventional double-J ureteral stent","Ureteral Stent Symptom Questionnaire","RECRUITING","2026-05-30",{"date":73,"type":40},"2026-06-04",{"date":75,"type":40},"2026-05-02",{"date":77,"type":21},"2027-05",{"name":79,"class":47},"Beni-Suef University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":107,"locationsCount":108},"100637967","phase-2-melatonin-and-solifenacin-for-double-j-ureteral-stent-symptoms-100637967","NCT07617922","Melatonin and Solifenacin for Double-J Ureteral Stent Symptoms","Melatonin Versus Solifenacin Versus Their Combination for Improving Double-J Ureteral Stent-Related Symptoms and Quality of Life: A Prospective Randomized Study","MEL-SOL-STENT","Inclusion Criteria:\n\n1. Age 18 to 60 years.\n2. Patients undergoing unilateral ureteroscopy or ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n3. Ability to understand and complete the study questionnaires.\n4. Willingness to participate and provide written informed consent.\n\nExclusion Criteria:\n\n1. Bilateral ureteral stents.\n2. Stents inserted for malignant ureteral obstruction or non-stone reconstructive indications.\n3. Known hypersensitivity or contraindication to solifenacin or melatonin.\n4. History of acute or chronic urinary retention, or evidence of clinically significant bladder outlet obstruction at baseline.\n5. History of narrow-angle glaucoma or other contraindications to antimuscarinic therapy, including gastric retention.\n6. Significant hepatic impairment.\n7. Severe renal impairment if judged clinically relevant to study medication safety.\n8. Pre-existing moderate to severe lower urinary tract symptoms unrelated to the stent.\n9. Recent use of antimuscarinics, alpha-blockers, or melatonin that may interfere with symptom assessment.\n10. Pregnancy or lactation.\n11. Inability to complete follow-up.","60 Years",{"count":90,"type":21},189,[92],"PHASE2","Double-J ureteral stents are commonly inserted after ureteroscopy, but they may cause bothersome urinary symptoms, pain, sleep disturbance, and reduced quality of life.\n\nThis prospective randomized assessor-blinded three-arm clinical trial will compare oral solifenacin, oral melatonin, and their combination for improving ureteral stent-related symptoms in adult patients after unilateral ureteroscopic lithotripsy with insertion of a unilateral Double-J ureteral stent.\n\nParticipants will be randomized to receive solifenacin 5 mg once daily, melatonin 3 mg once nightly, or combined solifenacin 5 mg once daily plus melatonin 3 mg once nightly for 14 days after surgery. The primary outcome is the total Ureteral Stent Symptom Questionnaire score at postoperative Day 7. Secondary outcomes include total Ureteral Stent Symptom Questionnaire score at Day 14, change in questionnaire score between Day 7 and Day 14, Insomnia Severity Index score, Visual Analogue Scale pain score, adverse events, treatment compliance, and rescue analgesic consumption.",[31,64,95],"Lower Urinary Tract Symptoms",[97,98,69,99,100],"Double-J ureteral stent","Ureteral stent symptoms","Solifenacin","Melatonin","2026-05-29",{"date":103,"type":40},"2026-06-02",{"date":105,"type":40},"2026-05-07",{"date":77,"type":21},{"name":79,"class":47},1]